Compare Stocks → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CLLSNASDAQ:DBVTNASDAQ:MOLNNASDAQ:ZURA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$3.06-5.6%$2.66$0.96▼$3.77$180.09M3.0884,803 shs131,617 shsDBVTDBV Technologies$0.58+1.8%$0.74$0.56▼$2.37$110.03M0.7354,955 shs91,106 shsMOLNMolecular Partners$3.80+2.7%$3.93$3.32▼$7.32$134.60M0.794,186 shs661 shsZURAZura Bio$4.68+1.7%$3.36$2.00▼$14.00$198.23M0.15311,997 shs164,766 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis-5.56%+2.34%+9.68%0.00%+59.38%DBVTDBV Technologies+0.96%-12.99%-24.59%-32.31%-65.09%MOLNMolecular Partners+2.67%-4.52%-6.40%-17.39%-42.77%ZURAZura Bio+1.74%+1.30%+68.35%+17.00%-25.60%The Crypto 9-5 Escape Plan (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLLSCellectis2.6826 of 5 stars3.52.00.00.03.32.50.6DBVTDBV Technologies1.9266 of 5 stars3.22.00.00.01.81.71.3MOLNMolecular Partners0.9631 of 5 stars2.03.00.00.02.70.01.3ZURAZura Bio3.7544 of 5 stars3.65.00.00.03.74.20.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLLSCellectis3.00Buy$8.50177.78% UpsideDBVTDBV Technologies2.33Hold$3.33478.70% UpsideMOLNMolecular Partners2.00Hold$4.5018.42% UpsideZURAZura Bio3.17Buy$18.83302.42% UpsideCurrent Analyst RatingsLatest CLLS, ZURA, MOLN, and DBVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/10/2024ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $21.005/8/2024DBVTDBV TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $5.005/3/2024ZURAZura BioPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$26.004/1/2024ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$17.00 ➝ $16.002/21/2024DBVTDBV TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 5/11/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLLSCellectis$9.19M18.51N/AN/A$1.52 per share2.01DBVTDBV Technologies$15.73M7.06N/AN/A$0.58 per share0.99MOLNMolecular Partners$7.84M17.63N/AN/A$5.41 per share0.70ZURAZura BioN/AN/AN/AN/A$1.85 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLLSCellectis-$101.06M-$1.72N/AN/AN/A-1,087.66%-99.88%-36.89%5/16/2024 (Estimated)DBVTDBV Technologies-$72.73M-$0.42N/AN/AN/A-530.89%-56.76%-43.18%7/29/2024 (Estimated)MOLNMolecular Partners-$69.04M-$2.12N/AN/AN/A-885.11%-31.10%-27.93%N/AZURAZura Bio-$69.24MN/A0.00N/AN/AN/A-60.23%-48.47%8/12/2024 (Estimated)Latest CLLS, ZURA, MOLN, and DBVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/29/2024Q4 2023CLLSCellectisN/A-$0.64-$0.64-$0.64N/A$1.99 million3/14/2024Q4 2023MOLNMolecular PartnersN/A-$0.68-$0.68-$0.68N/A$1.17 million3/7/2024Q4 2023DBVTDBV Technologies-$0.16-$0.06+$0.10-$0.06$1.10 million$8.88 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLLSCellectisN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLLSCellectis0.581.501.50DBVTDBV TechnologiesN/A4.514.26MOLNMolecular PartnersN/A13.3513.35ZURAZura BioN/A4.974.97OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLLSCellectis63.90%DBVTDBV Technologies71.74%MOLNMolecular Partners26.55%ZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipCLLSCellectis16.41%DBVTDBV Technologies0.71%MOLNMolecular Partners5.93%ZURAZura Bio15.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCLLSCellectis23155.58 million46.46 millionOptionableDBVTDBV Technologies104192.87 million191.50 millionOptionableMOLNMolecular Partners16736.37 million34.21 millionNot OptionableZURAZura Bio1443.09 million36.29 millionNot OptionableCLLS, ZURA, MOLN, and DBVT HeadlinesSourceHeadlineZura Bio Ltd (ZURA) Q1 2024 Earnings: Financial and Strategic Developmentsfinance.yahoo.com - May 10 at 4:01 PMZura Bio (NASDAQ:ZURA) Given New $21.00 Price Target at Oppenheimermarketbeat.com - May 10 at 3:58 PMZURA Stock Earnings: Zura Bio Beats EPS for Q2 2024investorplace.com - May 9 at 2:10 PMZura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlightsfinance.yahoo.com - May 9 at 7:36 AMZura Bio Limited (NASDAQ:ZURA) Receives $18.00 Consensus Target Price from Analystsamericanbankingnews.com - May 6 at 1:48 AMZura Bio (NASDAQ:ZURA) Coverage Initiated at Piper Sandleramericanbankingnews.com - May 5 at 3:52 AMPiper Sandler Initiates Coverage of Zura Bio (ZURA) with Overweight Recommendationmsn.com - May 4 at 4:30 PMAnalysts Are Bullish on These Healthcare Stocks: Irhythm Technologies (IRTC), Zura Bio (ZURA)markets.businessinsider.com - May 3 at 9:26 PMZura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of "Buy" by Brokeragesmarketbeat.com - May 3 at 9:31 AMZura Bio (NASDAQ:ZURA) Research Coverage Started at Piper Sandlermarketbeat.com - May 3 at 8:38 AMZura Bio Limited (ZURA)finance.yahoo.com - May 1 at 4:54 AMThese Biotechs and IPOs Inspire Big Insider Buying247wallst.com - April 28 at 8:15 AMZura Bio executive acquires $24,999 in company sharesinvesting.com - April 26 at 6:47 PMZura Bio EVP Kiran Nistala buys $10,000 in company sharesinvesting.com - April 26 at 6:47 PMKiran Nistala Buys 3,195 Shares of Zura Bio Limited (NASDAQ:ZURA) Stockinsidertrades.com - April 25 at 6:37 AMDirector Amit Munshi Acquires 159,744 Shares of Zura Bio Ltd (ZURA)finance.yahoo.com - April 25 at 5:33 AMZura Bio Limited (NASDAQ:ZURA) EVP Kiran Nistala Buys 3,195 Sharesmarketbeat.com - April 24 at 9:14 PMZura Bio stock jumps on plans to raise $112.5M in private financingmsn.com - April 20 at 10:39 AMZura Bio Announces Private Placement Of $112 MLn Of Class A Shares; Stock Upmarkets.businessinsider.com - April 18 at 3:17 PMZura Bio Shares Rise 16% After Private Placement Valued at $112.5Mmarketwatch.com - April 18 at 3:17 PMZura Bio Announces Oversubscribed $112.5 Million Private Placementfinance.yahoo.com - April 18 at 10:16 AMZura Bio Announces Robert Lisicki as CEO and Directorbusinesswire.com - April 8 at 6:00 AMZura Bio Stock (NASDAQ:ZURA), Analyst Ratings, Price Targets, Predictionsbenzinga.com - April 3 at 9:22 AMInsider Buyers At Zura Bio Recover Some Losses, But Still Down US$165kfinance.yahoo.com - April 2 at 8:24 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCellectisNASDAQ:CLLSCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.DBV TechnologiesNASDAQ:DBVTDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Molecular PartnersNASDAQ:MOLNMolecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Zura BioNASDAQ:ZURAZura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.